Inactivation of serum response factor contributes to decrease vascular muscular tone and arterial stiffness in mice

Circulation Research

Volumn 112, Issue 7, 2013, Pages 1035-1045

  Galmiche, Guillaume ^a,b   Labat, Carlos ^c   Mericskay, Mathias ^a   Aissa, Karima Ait ^c   Blanc, Jocelyne ^a   Retailleau, Kevin ^d   Bourhim, Mustapha ^c   Coletti, Dario ^a   Loufrani, Laurent ^d   Gao Li, Jacqueline ^a   Feil, Robert ^e   Challande, Pascal ^a   Henrion, Daniel ^d   Decaux, Jean François ^f   Regnault, Véronique ^c   Lacolley, Patrick ^c   Li, Zhenlin ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d CNRS   (France)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

aortas; carotid arteries; contractility; elasticity; relaxation; serum response factor; smooth muscle cell

Indexed keywords

COLLAGEN; ELASTIN; INTEGRIN; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN KINASE; MYOSIN PHOSPHATASE TARGET SUBUNIT 1; NITRIC OXIDE; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN KINASE C; PROTEIN KINASE C POTENTIATING MYOSIN PHOSPHATASE INHIBITOR; SERUM RESPONSE FACTOR; SMOOTH MUSCLE ACTIN; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; ELASTICITY; GENE INACTIVATION; GENE OVEREXPRESSION; GENE TARGETING; HEART MUSCLE CONTRACTILITY; IN VITRO STUDY; MESENTERIC ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SMOOTH MUSCLE TONE; TRANSGENIC ANIMAL; VASCULAR ENDOTHELIUM; VASCULAR RING; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL;

AGING; ANIMALS; AORTA; BLOOD PRESSURE; CAROTID ARTERIES; DISEASE MODELS, ANIMAL; ELASTICITY; MESENTERIC ARTERIES; MICE; MICE, KNOCKOUT; MICROSCOPY, ELECTRON, TRANSMISSION; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; MYOSIN LIGHT CHAINS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; SERUM RESPONSE FACTOR; TUNICA MEDIA; VASCULAR STIFFNESS; VASOCONSTRICTION; VASODILATION;

EID: 84876414429     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.113.301076     Document Type: Article

References (44)

1. Benetos A, Waeber B, Izzo J, Mitchell G, Resnick L, Asmar R, Safar M. Infuence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens. 2002;15:1101-1108.
2. Lacolley P, Challande P, Osborne-Pellegrin M, Regnault V. Genetics and pathophysiology of arterial stiffness. Cardiovasc Res. 2009;81:637-648.
3. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiol-ogy, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25:932-943.
4. Bezie Y, Lacolley P, Laurent S, Gabella G. Connection of smooth muscle cells to elastic lamellae in aorta of spontaneously hypertensive rats. Hypertension. 1998;32:166-169.
5. Mitchell GF, Guo CY, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, Vasan RS, Levy D. Cross-sectional correlates of increased aortic stiffness in the community: the Framingham Heart Study. Circulation. 2007;115:2628-2636.
6. Qiu H, Zhu Y, Sun Z, Trzeciakowski JP, Gansner M, Depre C, Resuello RR, Natividad FF, Hunter WC, Genin GM, Elson EL, Vatner DE, Meininger GA, Vatner SF. Short communication: vascular smooth muscle cell stiffness as a mechanism for increased aortic stiffness with aging. Circ Res. 2010;107:615-619.
7. Andreadis EA, Sfakianakis ME, Tsourous GI, Georgiopoulos DX, Fragouli EG, Katsanou PM, Tavoularis EI, Skarlatou MG, Marakomichelakis GE, Ifanti GK, Diamantopoulos EJ. Differential impact of angiotensin receptor blockers and calcium channel blockers on arterial stiffness. Int Angiol. 2010;29:266-272.
8. Ishimitsu T, Numabe A, Masuda T, Akabane T, Okamura A, Minami J, Matsuoka H. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res. 2009;32:962-968.
9. Mahmud A, Feely J. Effect of angiotensin ii receptor blockade on arterial stiffness: beyond blood pressure reduction. Am J Hypertens. 2002;15:1092-1095.
10. Lacolley P, Challande P, Boumaza S, Cohuet G, Laurent S, Boutouyrie P, Grimaud JA, Paulin D, Lamazière JM, Li Z. Mechanical properties and structure of carotid arteries in mice lacking desmin. Cardiovasc Res. 2001;51:178-187.
11. Louis H, Kakou A, Regnault V, Labat C, Bressenot A, Gao-Li J, Gardner H, Thornton SN, Challande P, Li Z, Lacolley P. Role of alpha1beta1-integrin in arterial stiffness and angiotensin-induced arterial wall hypertrophy in mice. Am J Physiol Heart Circ Physiol. 2007;293:H2597-H2604.
12. McDonald OG, Owens GK. Programming smooth muscle plasticity with chromatin dynamics. Circ Res. 2007;100:1428-1441.
13. Miano JM, Long X, Fujiwara K. Serum response factor: master regulator of the actin cytoskeleton and contractile apparatus. Am J Physiol Cell Physiol. 2007;292:C70-C81.
14. Olson EN, Nordheim A. Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol. 2010;11:353-365.
15. Chang J, Wei L, Otani T, Youker KA, Entman ML, Schwartz RJ. Inhibitory cardiac transcription factor, SRF-N, is generated by caspase 3 cleavage in human heart failure and attenuated by ventricular unloading. Circulation. 2003;108:407-413.
16. Chow N, Bell RD, Deane R, Streb JW, Chen J, Brooks A, Van Nostrand W, Miano JM, Zlokovic BV. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood fow dysregulation in Alzheimer's phenotype. Proc Natl Acad Sci USA. 2007;104:823-828.
17. Diguet N, Mallat Y, Ladouce R, Clodic G, Prola A, Tritsch E, Blanc J, Larcher JC, Delcayre C, Samuel JL, Friguet B, Bolbach G, Li Z, Mericskay M. Muscle creatine kinase defciency triggers both actin depolymeriza-tion and desmin disorganization by advanced glycation end products in dilated cardiomyopathy. J Biol Chem. 2011;286:35007-35019.
18. Gary-Bobo G, Parlakian A, Escoubet B, Franco CA, Clément S, Bruneval P, Tuil D, Daegelen D, Paulin D, Li Z, Mericskay M. Mosaic inactiva-tion of the serum response factor gene in the myocardium induces focal lesions and heart failure. Eur J Heart Fail. 2008;10:635-645.
19. Parlakian A, Charvet C, Escoubet B, Mericskay M, Molkentin JD, Gary-Bobo G, De Windt LJ, Ludosky MA, Paulin D, Daegelen D, Tuil D, Li Z. Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. Circulation. 2005;112:2930-2939.
20. Miano JM, Ramanan N, Georger MA, de Mesy Bentley KL, Emerson RL, Balza RO Jr, Xiao Q, Weiler H, Ginty DD, Misra RP. Restricted inactivation of serum response factor to the cardiovascular system. Proc Natl Acad Sci USA. 2004;101:17132-17137.
21. Mericskay M, Blanc J, Tritsch E, Moriez R, Aubert P, Neunlist M, Feil R, Li Z. Inducible mouse model of chronic intestinal pseudo-obstruction by smooth muscle-specifc inactivation of the SRF gene. Gastroenterology. 2007;133:1960-1970.
22. Retailleau K, Toutain B, Galmiche G, et al. Selective involvement of serum response factor in pressure-induced myogenic tone in resistance arteries. Arterioscler Thromb Vasc Biol. 2013;33:339-346.
23. Kühbandner S, Brummer S, Metzger D, Chambon P, Hofmann F, Feil R. Temporally controlled somatic mutagenesis in smooth muscle. Genesis. 2000;28:15-22.
24. Parlakian A, Tuil D, Hamard G, Tavernier G, Hentzen D, Concordet JP, Paulin D, Li Z, Daegelen D. Targeted inactivation of serum response factor in the developing heart results in myocardial defects and embryonic lethality. Mol Cell Biol. 2004;24:5281-5289.
25. Cohen S, Zhai B, Gygi SP, Goldberg AL. Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin flaments in muscle atrophy. J Cell Biol. 2012;198:575-589.
26. Xin M, Small EM, Sutherland LB, Qi X, McAnally J, Plato CF, Richardson JA, Bassel-Duby R, Olson EN. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 2009;23:2166-2178.
27. Han YJ, Hu WY, Chernaya O, Antic N, Gu L, Gupta M, Piano M, de Lanerolle P. Increased myosin light chain kinase expression in hypertension: Regulation by serum response factor via an insertion mutation in the promoter. Mol Biol Cell. 2006;17:4039-4050.
28. Franco CA, Mericskay M, Parlakian A, Gary-Bobo G, Gao-Li J, Paulin D, Gustafsson E, Li Z. Serum response factor is required for sprouting angiogenesis and vascular integrity. Dev Cell. 2008;15:448-461.
29. Boumaza S, Arribas SM, Osborne-Pellegrin M, McGrath JC, Laurent S, Lacolley P, Challande P. Fenestrations of the carotid internal elastic lamina and structural adaptation in stroke-prone spontaneously hypertensive rats. Hypertension. 2001;37:1101-1107.
30. Bézie Y, Lamazière JM, Laurent S, Challande P, Cunha RS, Bonnet J, Lacolley P. Fibronectin expression and aortic wall elastic modulus in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol. 1998;18:1027-1034.
31. Heerkens EH, Shaw L, Ryding A, Brooker G, Mullins JJ, Austin C, Ohanian V, Heagerty AM. alphaV integrins are necessary for eutrophic inward remodeling of small arteries in hypertension. Hypertension. 2006;47:281-287.
32. Ingber D. Integrins as mechanochemical transducers. Curr Opin Cell Biol. 1991;3:841-848.
33. Kakou A, Bézie Y, Mercier N, Louis H, Labat C, Challande P, Lacolley P, Safar ME. Selective reduction of central pulse pressure under angioten-sin blockage in SHR: role of the fbronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009;22:711-717.
34. Yin F, Hoggatt AM, Zhou J, Herring BP. 130-kDa smooth muscle myo-sin light chain kinase is transcribed from a CArG-dependent, internal promoter within the mouse mylk gene. Am J Physiol Cell Physiol. 2006;290:C1599-C1609.
35. Hirano K. Current topics in the regulatory mechanism underlying the Ca2+ sensitization of the contractile apparatus in vascular smooth muscle. J Pharmacol Sci. 2007;104:109-115.
36. Shimizu H, Ito M, Miyahara M, Ichikawa K, Okubo S, Konishi T, Naka M, Tanaka T, Hirano K, Hartshorne DJ. Characterization of the myosin-binding subunit of smooth muscle myosin phosphatase. J Biol Chem. 1994;269:30407-30411.
37. Feng J, Ito M, Nishikawa M, Okinaka T, Isaka N, Hartshorne DJ, Nakano T. Dephosphorylation of distinct sites on the 20 kDa myosin light chain by smooth muscle myosin phosphatase. FEBS Lett. 1999;448:101-104.
38. Fleming I, Busse R. NO: the primary EDRF. J Mol Cell Cardiol. 1999;31:5-14.
39. Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens. 1993;11:1375-1380.
40. Karantzoulis-Fegaras F, Antoniou H, Lai SL, Kulkarni G, D'Abreo C, Wong GK, Miller TL, Chan Y, Atkins J, Wang Y, Marsden PA. Characterization of the human endothelial nitric-oxide synthase promoter. J Biol Chem. 1999;274:3076-3093.
41. Sen-Banerjee S, Mir S, Lin Z, Hamik A, Atkins GB, Das H, Banerjee P, Kumar A, Jain MK. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation. 2005;112:720-726.
42. Zhang R, Min W, Sessa WC. Functional analysis of the human en-dothelial nitric oxide synthase promoter. Sp1 and GATA factors are necessary for basal transcription in endothelial cells. J Biol Chem. 1995;270:15320-15326.
43. Ohashi Y, Kawashima S, Hirata Ki, Yamashita T, Ishida T, Inoue N, Sakoda T, Kurihara H, Yazaki Y, Yokoyama M. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest. 1998;102:2061-2071.
44. van Deel ED, Merkus D, van Haperen R, de Waard MC, de Crom R, Duncker DJ. Vasomotor control in mice overexpressing human en-dothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol. 2007;293:H1144-H1153.